Sandoz’s Biosimilar Filgrastim ‘Highly Similar’ To Neupogen, FDA Staff Say
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA briefing documents prepared for the advisory committee probably are as positive as Sandoz could have hoped for, given that it is the first biosimilar sponsor in line for approval.